105 Views | 67 Downloads
Conceptualization: P.S., C.D.P., R.B., S.R., M.K., S.-M.K. and M.S.S.; Methodology: C.D.P., S.R., P.S., R.B., M.K., S.-M.K., K.M.J., L.J., S.-H.N., A.N.B., T.V.d.G., C.N.W. and L.L.; Investigation: R.B., L.E.M., J.O., K.-H.K., N.B., S.S., P.K. and J.T.L.B.; Funding acquisition: P.S., S.J.C.R., C.D.P. and S.-M.K.; Project administration: C.D.P., S.R., P.S., S.-M.K., M.K. and M.S.S.; Supervision: R.B., S.-M.K., P.S., S.R., C.D.P., M.S.S. and M.K.; Writing—original draft: R.B., S.-M.K., M.K., C.D.P. and S.R.; Writing—review and editing: P.S., S.-M.K., M.K. and M.S.S. All authors have read and agreed to the published version of the manuscript.
P.S. and S.J.C.R. are the co-founders of the Metaclipse Therapeutics Corporation (MTC) and hold equity and stock options. The corresponding author (P.S.) holds shares in Metaclipse Therapeutics Corporation, a company that is planning to use GPI-anchored molecules to develop a VLP-based vaccine in the future, as suggested in the current manuscript. C.D.P. and S.R. declare competing financial interests in the form of stock ownership and paid employment by Metaclipse Therapeutics Corporation. K.M.J., S.-H.N., A.N.B., L.J., T.V.G. and C.N.W. declare competing financial interests in the form of paid employment by Metaclipse Therapeutics Corporation. One or more embodiments of one or more patents and patent applications filed by Metaclipse Therapeutics Corporation and Emory University may encompass the methods, reagents, and data disclosed in this manuscript. All other authors have no competing interests to declare.
This research was funded by NIH/NIAID (SBIR Contract# 75N93019C00017 Amendment to Pack/Ramachandiran) and Intel Corporation for the Intel COVID-19 Global Technology Response Initiative grant. The animal study protocols were approved by the Institutional Animal Care and Use Committee (IACUC). IACUC protocol # 2017-00-504 (Emory University), Protocol number A20044 (Georgia State University).
© 2022 by the authors.